Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel

Last updated: October 8, 2020
Sponsor: Ciusss de L'Est de l'Île de Montréal
Overall Status: Completed

Phase

3

Condition

Cervical Cancer

Endometrial Cancer

Breast Cancer

Treatment

N/A

Clinical Study ID

NCT04237090
2020-2110
  • Ages > 18
  • All Genders

Study Summary

Explore the randomized, controlled, double-blind design targeted for the final clinical trial to assess the acceptability of interventions and clinical outcome measures and to provide data making it possible to estimate the parameters necessary for the preparation, modification or even abandonment of the final study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Receiving intravenous chemotherapy treatments at the Maisonneuve-Rosemont hospitaloutpatient oncology clinic

  • Starting their first lifetime treatment with paclitaxel (alone or in combination withother anticancer agents).

  • Capable of giving free and informed consent and who agrees to participate by signingthe consent form

  • Aged 18 and over

  • Able to complete questionnaires

Exclusion

Exclusion Criteria:

  • Does not understand French or English

  • Taking chronic H1 antagonist orally

  • Taking chronic systemic corticosteroids

  • Contraindication or possible medical danger, such as a documented allergy or previousintolerance, related to the administration of cetirizine, diphenhydramine, placebo orany ingredient in their formulation

  • Has received paclitaxel, docetaxel or paclitaxel nanoparticles linked to albumin inthe past

  • Receiving paclitaxel nanoparticles linked to albumin

  • Severe renal impairment (Cockcroft-Gault <10 milliliters/minute)

  • Pregnant or breastfeeding women

  • Receiving paclitaxel under desensitization protocol

  • Documented or reported dysphagia or other pathophysiological condition preventing atablet from being swallowed whole

  • Interactions preventing the full dose of oral cetirizine from being absorbed

  • Participating in another clinical trial simultaneously

Study Design

Total Participants: 27
Study Start date:
February 14, 2020
Estimated Completion Date:
September 04, 2020

Study Description

Paclitaxel is known to cause 30 to 40% of infusion-related reactions when no premedication is administered. It is agreed that all patients should receive premedication with dexamethasone, an H1 antagonist, such as diphenhydramine, and an H2 antagonist before the administration of paclitaxel. There are several cases where undesirable effects (eg. drowsiness, dry mouth, motor impatience) have been reported following the administration of this conventional premedication. Diphenhydramine is often accused because of its pharmacological properties.

A definitive, randomized, double-blind, non-inferiority study can assess whether cetirizine, a non-sedating H1 antagonist, can be used as an effective and safe alternative to diphenhydramine in the prevention of paclitaxel infusion-related reactions.

In the current proposed feasibility study, patients will be followed for the first two doses of paclitaxel. The goal is to explore the randomized, controlled, double-blind design targeted for the final clinical trial to assess the acceptability of interventions and clinical outcome measures and to provide data making it possible to estimate the parameters necessary for the preparation, modification or even abandonment of the final study.

Connect with a study center

  • CIUSSS de l'Est-de-l'île-de-Montréal

    Montréal, Quebec H1T 2M4
    Canada

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.